Potentially negative effects of AIDS vaccines based on recombinant viruses carrying HIV-1 derived envelope gene. A warning on AIDS vaccine development

Vaccine. 1993;11(3):291-2. doi: 10.1016/0264-410x(93)90189-5.

Abstract

Various candidate AIDS vaccines based on HIV-1 envelope glycoprotein (gp120/160) are currently under clinical trials (phase 1 and 2) in healthy, HIV-negative volunteers, as well as in HIV-infected persons. Most of these vaccines use recombinant viral vectors carrying the HIV-derived gp120/160 gene. Possible negative effects of recently reported sequence and gene similarities between HIV-1 gp120 and the variable region of human immunoglobulins on further development and current application of such AIDS vaccines are discussed.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS Vaccines / adverse effects*
  • AIDS Vaccines / immunology
  • Amino Acid Sequence
  • Gene Products, env / chemistry
  • Gene Products, env / genetics
  • Gene Products, env / immunology
  • HIV Envelope Protein gp120 / chemistry
  • HIV Envelope Protein gp120 / genetics
  • HIV Envelope Protein gp120 / immunology
  • HIV Envelope Protein gp160
  • HIV-1 / genetics*
  • HIV-1 / immunology
  • Humans
  • Immunoglobulin Variable Region / chemistry
  • Immunoglobulin Variable Region / genetics
  • Molecular Sequence Data
  • Protein Precursors / chemistry
  • Protein Precursors / genetics
  • Protein Precursors / immunology
  • Protein Structure, Secondary
  • Sequence Homology, Amino Acid

Substances

  • AIDS Vaccines
  • Gene Products, env
  • HIV Envelope Protein gp120
  • HIV Envelope Protein gp160
  • Immunoglobulin Variable Region
  • Protein Precursors